Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TiGenix NV

Division of Takeda Pharmaceutical Co. Ltd.
www.tigenix.com

Latest From TiGenix NV

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018

New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.

Approvals Europe

EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More

New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.
Approvals Europe

Bone Therapeutics: Helping Bone Regenerate, And To Knit Together

Executive Interview: A raft of clinical trial results are expected in the second half of 2018 for Bone Therapeutics' regenerative cell therapy approach to hip osteonecrosis and delayed-union fractures.

 

Clinical Trials Regenerative Medicine

Appointments: Top-Level Changes At J&J, Roche, Pierre Fabre, Nordic Nanovector, Inthera And DDF

This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Eduardo Bravo, Mng. Dir. & CEO
    Claudia D’Augusta, CFO
    Wilfried Dalemans, CTO
    Marie Paule Richard, MD, CMO
  • Contact Info
  • TiGenix NV
    Phone: (32) 16 39 60 60
    Romeinse Straat 12, Bus 2
    Leuven, B-3001
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register